Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study

Hidenori Inohara*, Takehiro Inoue, Shiro Akahani, Yoshifumi Yamamoto, Yukinori Takenaka, Takashi Nakagawa, Fumiaki Isohashi, Takeshi Kubo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: This phase I study of weekly low-dose administration of cisplatin (CDDP) and docetaxel (DOC) combined with concurrent conventionally fractionated radiotherapy was designed for locoregionally advanced head and neck cancer. Patients and Methods: Twelve patients were treated at varying levels of DOC (level 1: 5 mg/m2/week, level 2: 7.5 mg/m2/week, level 3: 10 mg/m2/week) with CDDP constant at 20 mg/m 2/week in four cohorts of three patients. Radiation was given at 1.8-2.0 Gy/fraction to a total dose of 60-70.2 Gy. Results: Hematological toxicities, except lymphocytopenia, were minimal. Mucosal toxicities, especially grade 3 mucositis, were common. Dose-limiting toxicity was grade 3 pain, although level 3 did not reach a maximum tolerated dose. No grade 4 toxicities were observed. Complete response rate ranged from 33% to 67% in the various dose levels. Conclusion: This concurrent chemoradiotherapy seems to be a promising treatment modality, in which level 3 is the recommended dose for a phase II study.

Original languageEnglish
Pages (from-to)4135-4140
Number of pages6
JournalAnticancer Research
Volume24
Issue number6
StatePublished - 2004/11

Keywords

  • Cisplatin
  • Concurrent chemoradiation
  • Docetaxel
  • Head and neck cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study'. Together they form a unique fingerprint.

Cite this